Martin Leivers

Martin Leivers

Company: GSK

Job title: Senior Director, Early Development Leader

Seminars:

Approaches for Direct Reduction of the Immunosuppressive HBs Antigen: Current Status & Outlook 12:00 pm

• Emerging clinical data points towards the need for both reduction of HBsAg levels alongside immunostimulation in order to achieve functional cure of CHB • A limited number of modalities and mechanisms which directly lower HBsAg have been demonstrated preclinically and clinically • Reviewing these mechanisms and considering how they may be used as part…Read more

day: Day One

Panel Discussion: What, When & How? Pursuing Combination Therapy to Improve Durable Efficacy & Decrease Viral Breakthrough 8:30 am

• Sequencing multiple mechanisms of action acting on immune and viral targets to optimize therapeutic effect • Identifying effective combinations to achieve treatment with finite durations • Measuring toxicity and adverse events in combination therapy for HBVRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.